Retrospective study of budesonide in children with eosinophilic gastroenteritis

Fang, Shengbo; Song, Yanqing; Zhang, Sixi; Li, Chunyan

doi:10.1038/s41390-019-0444-2

Cited by 9 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, objective data such as repeat biopsies were often unavailable for review in our cohort. However, studies have suggested that treatment with budesonide is safe and effective, with 1 recent study showing that it had a similar effect to prednisone in children ( 21 ). Our recommendation is to use this agent first line, particularly in patients with severe forms of disease.…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course

Havlichek

Choung

Murray

2021

Clinical and Translational Gastroenterology

View full text Add to dashboard Cite

INTRODUCTION: Studies on eosinophilic gastroenteritis have identified broad spectrums of disease. We aimed to characterize subtypes of disease and ascertain outcomes of each group. METHODS: This is a retrospective cohort study from a large tertiary medical center including 35 patients diagnosed with eosinophilic gastroenteritis from 2007 to 2018. We defined 2 groups of patients based on clinical and laboratory findings at presentation. Severe disease was defined as having weight loss at time of presentation, hypoalbuminemia at presentation, serosal disease involvement, or anemia at diagnosis. The remaining patients were labeled as mild disease group. We collected and compared demographic data, clinical features, laboratory findings, an allergy history, and disease course of both cohorts. RESULTS: Among 35 patients with eosinophilic gastroenteritis, 18 patients met the criteria for severe disease and 17 patients for mild disease. Of the patients with severe eosinophilic gastroenteritis, 6 (38%) had remission without chronic symptoms, whereas 10 (63%) had chronic symptoms requiring chronic medical therapy. Of the mild group, 12 patients (80%) had disease remission without chronic medications. An allergy history was more common in the severe disease group (83%) compared with the mild disease group (45%). Prednisone and open capsule budesonide were the most commonly used treatment medications in both groups. DISCUSSION: Patients with eosinophilic gastroenteritis may be characterized into 2 forms. Patients with weight loss at time of presentation, hypoalbuminemia at presentation, serosal disease involvement, or anemia at diagnosis were associated with a chronic disease course requiring chronic medications.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course

Havlichek

Choung

Murray

2021

Clinical and Translational Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Thus, systemic exposure can be minimized. In addition to effectively alleviating Crohn’s disease, autoimmune hepatitis, and ulcerative colitis in adults[ 25 - 27 ], a recent small-scale retrospective study showed that budesonide is effective in children with eosinophilic gastroenteritis[ 28 ]. In our clinical practice of the 22 children, methylprednisolone/montelukast and budesonide did be effective in the clinical and pathological remission of eosinophil gastroenteritis in children.…”

Section: Discussionmentioning

confidence: 99%

Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series

Chen¹,

Sun²

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Eosinophilic gastroenteritis is a rare inflammatory disorder in children. However, there is still no standard guideline in the treatment of pediatric eosinophilic gastroenteritis. AIM To report our experience with the diagnosis and treatment of children with eosinophilic gastroenteritis. METHODS From January 2017 to December 2019, a total of 22 children were diagnosed with eosinophilic gastroenteritis. RESULTS Endoscopic examination showed eosinophil infiltration in the duodenum [mean number of eosinophils/high-power field (HPF) = 53.1 ± 81.5], stomach (mean number of eosinophils/HPF = 36.8 ± 50.5), and terminal ileum (mean number of eosinophils/HPF = 49.0 ± 24.0). All 18 children with low eosinophil infiltration (< 14%) responded well to the initial drug treatment without relapse, while two of four children with high eosinophil infiltration (> 14%) relapsed after initial methylprednisolone/montelukast treatment. In addition, children with high eosinophil infiltration (> 14%) showed symptomatic relief and histological remission without further relapse after receiving budesonide/methylprednisolone as initial or relapse treatment. CONCLUSION Methylprednisolone/montelukast is still the best treatment for children with low eosinophil infiltration (< 14%). Budesonide can be considered as the initial or relapse treatment for children with high eosinophil infiltration (> 14%).

show abstract

Effects of montelukast sodium plus budesonide on lung function, inflammatory factors, and immune levels in elderly patients with asthma

Zhang

Liu

2020

Ir J Med Sci

View full text Add to dashboard Cite

Retrospective study of budesonide in children with eosinophilic gastroenteritis

Cited by 9 publications

References 22 publications

Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course

Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course

Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series

Effects of montelukast sodium plus budesonide on lung function, inflammatory factors, and immune levels in elderly patients with asthma

Contact Info

Product

Resources

About